Compare Amgen, Inc. (AMGN) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Altria Group Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Altria Group Inc trades at $72.05 (market cap $119.88B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (5.91%). Which is the better fit depends on your goals.
| AMGN | MO | |
|---|---|---|
Market Cap | $196.12B | $119.88B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $74.55 |
52-Week Low | $271.18 | $54.72 |
Enterprise Value | $241.41B | $140.95B |
Dividend Yield | 2.77% | 5.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $360.45, down 0.81% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly EPS beats. Revenue grew to $36.75B in 2025 with a net income margin of 20.96%, though high debt levels and recent regulatory challenges for Tavneos in Europe present headwinds. Analyst sentiment is positive with 57.9% buy ratings and a consensus price target of $351.29.
The outlook for AMGN is cautiously optimistic, supported by earnings momentum and a diversified product portfolio, but investors face risks from patent expirations, competitive biosimilar pressures, and regulatory setbacks. The stock's current price near consensus target suggests limited near-term upside, requiring careful monitoring of pipeline developments and debt management.
Altria Group (MO) trades at $71.87, up 0.14% with neutral technical signals. The stock shows strong fundamentals with a P/E of 14.99, net income margin of 39.52%, and consistent dividend payments including the recent $1.06 dividend. Recent earnings beat expectations in Q1 2026 with EPS of $1.32 versus $1.25 expected. Cash flow from operations remains robust at $9.29B for 2025, supporting the company's financial stability.
Outlook remains positive with analyst consensus at Buy (61.53%) and price target of $71.00. Key risks include regulatory pressures on tobacco products and declining smoking trends, offset by strong pricing power and diversification into oral nicotine. The stock offers attractive income with defensive qualities in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
